WaveRx, a Waltham, MA-based developer of treatments for dermatological disorders, has shut its doors, according to a report in Dow Jones VentureWire today. The firm raised $502,512 las year, and raised about $6.8 million of an $11.6 million equity financing in 2009, according to an SEC document. Its investors, 5Am Ventures, Three Arch Partners, and Polaris Venture Partners, decided to close the company last year as it waited to hear back from the FDA on a clinical trial WaveRx had updated and shifted, following a number of delays, VentureWire reported. Today a call to the company was met with an automated message stating the number is out of service.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
